{
    "Trade/Device Name(s)": [
        "Glucose assay for the ADVIA IMS\u00ae System",
        "ADVIA IMS\u00ae Glucose",
        "Bayer ADVIA\u00ae 1650 Glucose Hexokinase II"
    ],
    "Submitter Information": "Bayer HealthCare LLC Diagnostics Division",
    "510(k) Number": "K052163",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFR"
    ],
    "Summary Letter Date": "October 11, 2005",
    "Summary Letter Received Date": "September 1, 2005",
    "Submission Date": "August 31, 2005",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine",
        "Cerebrospinal fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ADVIA IMS\u00ae System"
    ],
    "Method(s)/Technology(ies)": [
        "Hexokinase (HK) enzymatic method",
        "Glucose-6-phosphate dehydrogenase (G6PD) enzymatic method"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA IMS\u00ae Glucose assay measuring glucose via hexokinase and G6PD enzymatic methods on ADVIA IMS\u00ae System.",
    "Indications for Use Summary": "In vitro diagnostic assay for measuring glucose in human serum, plasma (lithium heparin), urine, and cerebrospinal fluid to aid in diagnosis, monitoring, and treatment of carbohydrate metabolism disorders such as diabetes mellitus and neonatal hypoglycemia.",
    "fda_folder": "Clinical Chemistry"
}